Moderna Stock Is at a Crossroads. Is the Path Ahead One of Profit or Pain for MRNA?

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...
GlobalData on MSN

Funds dry up for mRNA vaccines amid US political storm

This culminated in a $500m funding cut to mRNA vaccine research funding, impacting around 22 projects being run at the Biomedical Advanced Research and Development Authority (BARDA). Grants withdrawn ...

Could Covid-19 vaccines secretly boost cancer survival? Scientists say mRNA shows unexpected potential to aid cancer treatment

New research suggests Covid-19 mRNA vaccines offer benefits beyond viral protection. These vaccines may boost the immune ...
ABC7

Technology used to make COVID vaccines tested to treat HIV, cancer, more

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...
Pharmaceutical Technology

Venture financing for mRNA-based vaccines declines 82% in 2025 YTD

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m in the 2025's year to date (YTD), according to GlobalData’s Pharma ...